Agios Pharms Inc Drug Patent Portfolio
Agios Pharms Inc owns 1 orange book drug protected by 10 US patents Given below is the list of Agios Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11878049 | Mitapivat therapy and modulators of cytochrome P450 | 31 Jul, 2041 | Active |
| US11254652 | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | 21 Nov, 2038 | Active |
| US11234976 | Methods of using pyruvate kinase activators | 11 Oct, 2038 | Active |
| US11793806 | Pyruvate kinase activators for use in therapy | 12 Apr, 2033 | Active |
| US9193701 | Pyruvate kinase activators for use in therapy | 26 Oct, 2032 | Active |
| US10632114 | Pyruvate kinase activators for use in therapy | 03 May, 2032 | Active |
| US9682080 | Pyruvate kinase activators for use in therapy | 03 May, 2032 | Active |
| US9980961 | Pyruvate kinase activators for use in therapy | 03 May, 2032 | Active |
| US8785450 | Therapeutic compounds and compositions | 24 Feb, 2031 | Active |
| USRE49582 | Therapeutic compounds and compositions | 24 Feb, 2031 | Active |
Latest Legal Activities on Agios Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Agios Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9193701 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US9193701 |
| Mail Patent eCofC Notification | 27 Feb, 2024 | US11878049 |
| Patent eCofC Notification | 27 Feb, 2024 | US11878049 |
| Recordation of Patent eCertificate of Correction | 27 Feb, 2024 | US11878049 |
|
Email Notification
Critical
| 27 Feb, 2024 | US11878049 |
| Post Issue Communication - Certificate of Correction | 05 Feb, 2024 | US11878049 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Jan, 2024 | US11878049 |
|
Email Notification
Critical
| 23 Jan, 2024 | US11878049 |
| Mail Patent eGrant Notification | 23 Jan, 2024 | US11878049 |
| Patent eGrant Notification | 23 Jan, 2024 | US11878049 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Jan, 2024 | US11878049 |
| Recordation of Patent eGrant | 23 Jan, 2024 | US11878049 |
|
Email Notification
Critical
| 04 Jan, 2024 | US11878049 |
|
Issue Notification Mailed
Critical
| 03 Jan, 2024 | US11878049 |
Agios Pharms Inc's Family Patents
Agios Pharms Inc drugs have patent protection in a total of 42 countries. It's US patent count contributes only to 20.7% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Agios Pharms Inc Drug List
Given below is the complete list of Agios Pharms Inc's drugs and the patents protecting them.
1. Pyrukynd
Pyrukynd is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11878049 | Mitapivat therapy and modulators of cytochrome P450 |
31 Jul, 2041
(16 years from now)
| Active |
| US11254652 | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
21 Nov, 2038
(13 years from now)
| Active |
| US11234976 | Methods of using pyruvate kinase activators |
11 Oct, 2038
(13 years from now)
| Active |
| US11793806 | Pyruvate kinase activators for use in therapy |
12 Apr, 2033
(7 years from now)
| Active |
| US9193701 | Pyruvate kinase activators for use in therapy |
26 Oct, 2032
(7 years from now)
| Active |
| US10632114 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| US9682080 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| US9980961 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| US8785450 | Therapeutic compounds and compositions |
24 Feb, 2031
(5 years from now)
| Active |
| USRE49582 | Therapeutic compounds and compositions |
24 Feb, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pyrukynd's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List